2,2,2- trifluoro- N- (1- ((1- (4- fluorophenyl)- 1H- indazol- 5- yl)oxy)- 1- (3- methoxyphenyl)- 2- propanyl)acetamide

12/01/2016 - "AZD5423 is a selective glucocorticosteroid receptor modulator developed for the inhaled use in asthma and COPD. "
01/15/2015 - "Twenty subjects with mild allergic asthma were randomized to receive 7 days of treatment with nebulized AZD5423 (75 or 300 μg) once daily, budesonide 200 μg twice daily via Turbuhaler, or placebo in a double-blind, four-period, crossover design study. "
10/01/2017 - "Neither AZD5423, at doses which have shown to be efficacious in allergen-induced asthma, nor the reference control, at double the approved dose, had any clinically meaningful effect in the patient population studied in regard to lung function or markers of inflammation. "
01/01/2017 - "AZD5423 is a non-steroidal glucocorticoid receptor modulator, with low aqueous solubility, developed for treatment of asthma and COPD. "
10/01/2017 - "AZD5423 is a novel, inhaled, selective glucocorticoid receptor modulator (SGRM), which in an allergen challenge model in asthma patients improved lung function and airway hyper-reactivity. "

11/01/2022 - "Importantly, AZD5423 exerts effective protection against cisplatin- and ischemia/reperfusion (I/R)-induced AKI mouse model. "

10/01/2017 - "This study suggests that the selected population of patients with COPD does not respond to treatment with AZD5423 as regards lung function, while showing the expected systemic effects. "
10/01/2017 - "In the current trial, AZD5423 was for the first time tested in patients with chronic obstructive pulmonary disease (COPD). "
10/01/2017 - "It cannot be ruled out that a favourable lung function response of AZD5423 can be evoked using another experimental setting and/or within a different population of patients with COPD."
12/01/2016 - "AZD5423 is a selective glucocorticosteroid receptor modulator developed for the inhaled use in asthma and COPD. "
10/01/2017 - "In this double-blind, randomized and parallel group study, we examined airway and systemic effects of two doses of AZD5423, inhaled via Turbuhaler for 12 weeks, in 353 symptomatic patients with COPD (average pre-bronchodilator forced expiratory volume in one-second (FEV1) at screening was 50-52% of predicted normal). "

10/26/2017 - "The first clinical candidate 1b (AZD5423) displayed a potent inhibition of lung edema in a rat model of allergic airway inflammation following dry powder inhalation combined with a moderate systemic GR-effect, assessed as thymic involution. "
10/01/2017 - "Neither AZD5423, at doses which have shown to be efficacious in allergen-induced asthma, nor the reference control, at double the approved dose, had any clinically meaningful effect in the patient population studied in regard to lung function or markers of inflammation. "

01/15/2015 - "AZD5423 at 300 μg significantly attenuated allergen-induced airway hyperresponsiveness at 24 hours after allergen challenge versus placebo (P < 0.05). "